ARCHIVES

Ethicists dispute von Eschenbach’s claim that his NCI-FDA conflicts are managed. NCI-FDA chief appears to cite Klausner-era “in-box rule.”

This article is from The Cancer Letter archive.

Vol. 31 No. 46 | December 16, 2005

Download PDF Visit The Full Archive

Related Articles

The Avastin Story In A Nutshell: A Timeline

May 27, 2011

“We Will Move Forward With Bold Expectations,” NCI Director Says

October 2, 1998

Unclear Whether Insurance Will Cover AACR Losses

April 25, 2003

In Brief: NCI Seeks Better Ways to Make Available Fresh Tissue; Iverson Heads Cancer Control Science

October 5, 1984

President Asks ‘Standstill’ FY 1976 Budget For NCI, $123 Million Slash From ’75 Spending

February 7, 1975

ODAC Advice Poses Challenge to FDA: Would Iressa Approval Erode Standards?

November 8, 2002